Embed

Academic

Authors

Enzo Ballatori

Enzo Ballatori,Università degli Studi di Perugia,Oncology,Immunology,Diseases

Edit

Enzo Ballatori

Università degli Studi di Perugia

Publications: 18 | Citations: 166

Fields: Oncology, Immunology, Diseases

Collaborated with 88 co-authors from 1979 to 2011 | Cited by 612 authors

Cumulative Annual

Sort by:

Publications (18)

BibTeX | RIS | RefWorks Download

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

, , , , , , , , , , ,

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 19, no. 10, pp. 25-32, 2011

Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential

, , , , ,

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 19, no. 10, pp. 33-36, 2011

Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey

, , , , , , ,

Published in 2009.

Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens (Citations: 18)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=32710196&selfId1=54024143&selfId2=0&maxNumber=12&query=

Journal: British Journal of Haematology - BRIT J HAEMATOL , vol. 89, no. 4, pp. 780-789, 2008

The impact of chemotherapy-induced nausea and vomiting on health-related quality of life (Citations: 15)

, , , , , , , , ,

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 15, no. 2, pp. 179-185, 2007

Sort by:

Citations (166 times by 154 publications)

Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study (Citations: 3)

, , , , , ,

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 19, no. 7, pp. 963-969, 2011

Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting (Citations: 2)

, ,

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 19, no. 1, pp. 131-140, 2011

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy (Citations: 1)

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 19, no. 6, pp. 807-813, 2011

Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population (Citations: 1)

, , , ,

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 19, no. 6, pp. 843-851, 2011

Antiemetic drugs in oncology: pharmacology and individualization by pharmacogenetics

, , , , , ,

Published in 2011.

Comments

Co-authors (88)

Journals (8)

Keywords (50)

Enzo Ballatori,Università degli Studi di Perugia,Oncology,Immunology,Diseases

Publications (18)

BibTeX | RIS | RefWorks Download

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential

Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey

Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens (Citations: 18)

The impact of chemotherapy-induced nausea and vomiting on health-related quality of life (Citations: 15)

Citations (166 times by 154 publications)

Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study (Citations: 3)

Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting (Citations: 2)

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy (Citations: 1)

Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population (Citations: 1)

Antiemetic drugs in oncology: pharmacology and individualization by pharmacogenetics


	View FAQ about top research areas and Fields of study

Enzo Ballatori,Università degli Studi di Perugia,Oncology,Immunology,Diseases

Publications (18) BibTeX | RIS | RefWorks Download

Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens (Citations: 18)

The impact of chemotherapy-induced nausea and vomiting on health-related quality of life (Citations: 15)

Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study (Citations: 3)

Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting (Citations: 2)

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy (Citations: 1)

Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population (Citations: 1)

Publications (18)

BibTeX | RIS | RefWorks Download